In April 2024 the U.S. Environmental Protection Agency did something it had never done before: it set legally enforceable federal limits on a family of synthetic chemicals in drinking water, capping two of the most notorious — PFOA and PFOS — at four parts per trillion, roughly the lowest level laboratories can reliably detect [source: US EPA, 2024]. Around the same time, the manufacturer 3M finalized a settlement with U.S. public water systems worth up to $10.3 billion in present value to help pay for testing and cleanup [source: 3M, 2024]. A year later, in May 2025, the same EPA announced it would keep the limits for PFOA and PFOS but rescind the ones it had just set for several other PFAS, and push the compliance deadline back to 2031 [source: US EPA, 2025].
That whiplash — first-ever limits, billion-dollar settlements, then a partial rollback — is the story of "forever chemicals" in miniature. It is easy to read it as either an unfolding catastrophe or a regulatory overreaction, and both readings miss the same thing. Making sense of PFAS means holding several distinct questions apart: what is actually measured in our water and blood, versus what has been proven to cause harm; what a settlement or a hazard label legally means, versus what it says about risk; and the one genuinely settled fact — that these chemicals do not break down — versus the temptation to spin that fact into either certain doom or a shrug.
What PFAS are, and why "forever"
PFAS stands for per- and polyfluoroalkyl substances, a family of thousands of synthetic chemicals — more than 12,000 appear on the EPA's master list — engineered since the 1940s to repel water, oil, and heat [source: NIEHS, 2025]. They are what makes a pan non-stick, a jacket waterproof, a food wrapper grease-resistant, and a firefighting foam able to smother a fuel fire. Their usefulness and their problem come from the same place: the carbon–fluorine bond.
That bond is one of the strongest in all of organic chemistry. Fluorine grips carbon so tightly that the resulting molecules resist water, oxidation, heat, and — crucially — the enzymes and microbes that break down almost everything else in nature. This is why the label "forever chemicals" stuck. PFAS do not meaningfully degrade in the environment on any human timescale, and they accumulate: in soil, in water, in the bodies of animals, and in us. The persistence itself is not scientifically controversial. What persistence implies for health at the levels most people encounter is where the real argument lives.
What is actually measured
Start with what can be counted rather than debated. Since 1999 the U.S. Centers for Disease Control and Prevention has measured PFAS in Americans' blood through its national health survey, and the finding has been consistent and striking: at least one PFAS is detectable in the blood of the vast majority of the population — on the order of 97 to 99 percent of people tested [source: CDC/NHANES, 2024]. By that measure, PFAS exposure is essentially universal in the industrialized world.
But "detectable" is a measurement, not a diagnosis, and the trend line complicates the doom narrative in an important way. After manufacturers phased out the two legacy compounds PFOA and PFOS in the early 2000s, blood levels fell sharply. Between 1999–2000 and 2018, average PFOS in Americans' blood dropped by more than 85 percent and PFOA by more than 70 percent [source: CDC/NHANES, 2024]. Both facts are true at once: nearly everyone still carries measurable PFAS, and the burden of the worst legacy compounds has fallen dramatically as regulation and industry action took hold. A story that mentions only the first number is scaring you; a story that mentions only the second is reassuring you. The measurement supports neither on its own.
The regulation: first limits, then a retreat
The April 2024 rule was a landmark precisely because there had never been an enforceable federal ceiling for these chemicals in tap water. The EPA set the maximum contaminant level for PFOA and PFOS at 4.0 parts per trillion each, with three others — PFHxS, PFNA, and the newer replacement GenX — capped at 10 parts per trillion, and a combined limit for certain mixtures [source: US EPA, 2024]. A part per trillion is an almost unimaginably small quantity, and setting PFOA and PFOS at the edge of what instruments can detect signaled how seriously the agency treated them. The rule was projected to reduce exposure for around 100 million people.
Then came the reversal. In May 2025 the EPA announced it would uphold the PFOA and PFOS limits but rescind and reconsider the newly set limits for PFHxS, PFNA, and GenX, along with the mixture rule, while proposing to extend the compliance deadline for water systems from 2029 to 2031 [source: US EPA, 2025]. This is the crucial point that a headline about "the PFAS rule" often misses: the U.S. framework is not fixed. It is a contested, evolving standard, with the two best-studied compounds still regulated and the newer ones back in limbo. Regulation is administrative action, and administrative action can move in both directions.
The settlements: resolved claims, not verdicts
The dollar figures are the part of the PFAS story that travels fastest, and the part most often misread. 3M's settlement with public water systems commits the company to pay up to $10.3 billion in present value — capped at $12.5 billion nominally — over 13 years to fund PFAS testing and treatment, with final court approval in March 2024 and payments beginning that year [source: 3M, 2024]. Separately, DuPont, Chemours, and Corteva agreed to a roughly $1.18 billion settlement with public water providers in June 2023 [source: DuPont/Chemours/Corteva, 2023].
These are enormous numbers, and it is tempting to treat them as proof of guilt. Legally, they are not. Both settlements resolve claims without the companies admitting liability, and — more important for the science — a settlement is a business and legal decision to fund cleanup and cap litigation risk, not a court's finding that PFAS at any particular concentration caused any particular person's illness. The money tells you that contamination is widespread enough, and litigation costly enough, that manufacturers chose to pay to make the cases go away. That is a real and revealing fact about scale and exposure. It is not, on its own, an epidemiological verdict on causation.
Europe's different bet: regulate the whole class
While the U.S. regulates PFAS compound by compound, Europe is attempting something far broader. In January 2023, five countries — Denmark, Germany, the Netherlands, Norway, and Sweden — submitted to the European Chemicals Agency a proposal to restrict essentially the entire PFAS class under the REACH framework, one of the most sweeping chemical restrictions ever attempted [source: ECHA, 2025]. Rather than chase thousands of individual substances one lawsuit and one limit at a time, the logic is to treat persistence itself as the hazard and restrict the group.
That ambition brings friction. The 2023 consultation drew more than 5,600 comments, and in August 2025 the submitting countries published an updated proposal that assessed more industrial sectors and expanded the list of exemptions, including for certain fluoropolymers used in demanding applications [source: ECHA, 2025]. The agency's scientific committees are working toward final opinions by the end of 2026, after which the European Commission and member states would decide on any actual restriction. Like the U.S. rule, in other words, Europe's approach is real, serious, and not yet settled — a direction of travel, not a finished law.
The health evidence, weighed honestly
This is the layer where calibration matters most, because it is the easiest to overstate in either direction. The most consequential recent development came in November 2023, when the World Health Organization's International Agency for Research on Cancer classified PFOA as "carcinogenic to humans" — its highest category, Group 1 — and PFOS as "possibly carcinogenic to humans," Group 2B [source: IARC, 2023]. The Group 1 label for PFOA is significant, but it is widely misunderstood. IARC classifies hazard — whether a substance can cause cancer under some conditions — not risk, which depends on dose and exposure. A Group 1 listing puts PFOA in a category that also contains sunlight and processed meat; it does not by itself say how much cancer any given water or blood level will cause.
Beyond that specific classification, the broader health picture is genuinely mixed, and the most authoritative bodies say so plainly. The CDC's Agency for Toxic Substances and Disease Registry describes the epidemiological evidence as showing associations — not proven causation — between some PFAS and effects including raised cholesterol, a weaker antibody response to vaccines, changes in liver enzymes, pregnancy-induced high blood pressure, small reductions in birth weight, and kidney and testicular cancer [source: ATSDR, 2024]. It stresses that findings are sometimes inconsistent and that understanding is still evolving. In 2022 the National Academies took the evidence seriously enough to recommend that clinicians offer blood testing to highly exposed patients, while grading the strength of the evidence differently for each health outcome [source: NASEM, 2022].
Put together, the honest summary is neither "PFAS are proven to be devastating at any dose" nor "there's no real evidence of harm." For a few outcomes the evidence is fairly strong; for many it is associational and still being worked out; and a hazard classification, however serious, is not the same as a measured risk at the levels in your tap water.
Staying calibrated
The forever-chemicals story invites two equal and opposite errors. The first is catastrophizing: because the chemicals are persistent, nearly universal in our blood, and now carry a Group 1 cancer label for one compound, every exposure must be a slow poisoning. The second is minimizing: because levels are falling, because "the dose makes the poison," and because most health links are associational rather than proven, the whole thing must be overblown litigation and regulatory theater.
Both readings cherry-pick. The persistence is real and permanent; the near-universal detection is real; the strongest evidence for certain effects is real. And so is the sharp decline in legacy exposure, the distinction between a hazard label and a dose-response risk, and the fact that most health associations have not been established as causation. A calibrated view holds all of it: PFAS are a legitimate environmental problem worth stringent regulation and expensive cleanup, and the specific magnitude of harm at typical exposures remains a genuinely open scientific question.
What to watch
Three developments will tell you where this is heading. The first is the fate of the EPA's 2025 rollback — whether the rescinded limits are rewritten, litigated back into force, or left off the books, and whether the extended 2031 deadline holds. The second is Europe's decision after its scientific committees report at the end of 2026, which will show whether regulating PFAS as an entire class is workable or collapses under its exemptions. The third is the science itself: whether the associational health links harden into established causation, or whether some fade, as the next generation of studies matures.
Until then, the useful posture is the one the evidence actually supports. These chemicals earn their nickname — they really do last more or less forever — and that alone justifies treating the contamination seriously. But "forever" describes how long they persist, not how much harm they do at the levels in a given glass of water. Take the persistence seriously; hold the risk estimates with the humility the science still requires.